Cytochrome P450 in living donor liver transplantation

Journal of Biomedical Science

Chao-Long Chen¹  Shigeru Goto¹  Yu-Fan Cheng¹  Ching-Yin Huang¹  Chia-Yun Lai¹  Li-Wen Hsu¹  Kuang-Den Chen¹  Toshiaki Nakano¹  King-Wah Chiu¹ 

[1] Liver transplantation program, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, 123 Ta-Pei Road, Niao-Sung District 833, Kaohsiung, Taiwan

关键词: Homogenous phenomenon;    Pyrosequencing;    Living donor liver transplantation;    MDR1;    CYP3A5;    CYP3A4;    CYP2C19;    Cytochrome P450;   

Others  :  1213951
DOI  :  10.1186/s12929-015-0140-4

 received in 2015-03-27, accepted in 2015-04-30,  发布年份 2015

【 摘 要 】

Cytochrome P450 metabolizes many drugs in the liver. Three genotypes of CYP2C19 with extensive, intermediate, and poor metabolizing activity, respectively, have been identified in peripheral blood of transplant recipients and new liver grafts in living donor liver transplantation (LDLT). The expression of the final genotype in liver graft biopsies depends on the donor, whereas the expression in peripheral blood mononuclear cells depends on the recipient. The metabolizing isoenzyme of the major anti-rejection agents passes through CYP3A4, CYP3A5 and MDR1, which have also been identified to have similar biological characteristics as genotype of CYP2C19 in liver tissue. Recently, pyrosequencing has been used to investigate the expressions of different genotypes in liver grafts in LDLT. This review focuses on recent findings regarding the biological expressions of the CYP2C19, CYP3A4, CYP3A5 and MRD1 genotypes in liver grafts before and after LDLT. The application of pyrosequencing may be beneficial in further research on liver transplantation. Laser capture microdissection of hepatocytes in liver grafts may be a direction for future research.

【 授权许可】

   
2015 Chiu et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Berno G, Zaccarelli M, Gori C, Tempestilli M, Pucci L, Antinori A, Perno CF, Pucillo LP, D'Arrigo R. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. J Int AIDS Soc. 2014; 17(4 Suppl 3):19589.
• [2]Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013; 38(9):1129-1137.
• [3]Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol. 2014; 70(9):1073-1078.
• [4]Chiu KW, Tai WC, Nakano T, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL. Donor Graft does not Affect P450 2C19 Genotype Expressed on Peripheral Blood in Recipient with Living Donor Liver Transplantation. Clinical Transplant. 2010; 24(6):830-834.
• [5]Chiu KW, Nakano T, Hu TH, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL. CYP2C19 genotypes and graft pathology in recipients after liver transplantation. Ann Transpl. 2010; 15(4):38-43.
• [6]Kóbori L, Kõhalmy K, Porrogi P, Sárváry E, Gerlei Z, Fazakas J, Nagy P, Járay J, Monostory K. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br J Clin Pharmacol. 2008; 65(3):428-436.
• [7]Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19(1):25-35.
• [8]Chiu KW, Chen YS, de Villa VH, Wang CC, Eng HL, Wang SH, Liu PP, Jawan B, Huang TL, Cheng YF, Chen CL. Characterization of liver enzymes on living related liver transplantation patients with acute rejection. Hepato-Gastroenterol. 2005; 52(66):1825-1817.
• [9]Chiu KW, Nakano T, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL. CYP2C19 activity of liver tissues in western blot analysis on living donor liver transplantation. Hepatogastroenterology. 2012; 59(115):805-808.
• [10]Chiu KW, Nakano T, Hu TH, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL. Homogenous phenomenon of graft liver CYP2C19 genotypes after living donor liver transplantation. Eur J Clin Invest. 2012; 42(4):352-356.
• [11]Chiu KW, Nakano T, Chen KD, Lai CY, Hsu LW, Chiu HC, Huang CY, Cheng YF, Goto S, Chen CL. Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation. Plos One. 2013; 8(8):e71314.
• [12]Chiu KW, Nakano T, Chen KD, Hsu LW, Lai CY, Chiu HC, Huang CY, Cheng YF, Goto S, Chen CL. Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation. World J Hepatol. 2013; 5(11):642-8.
• [13]Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics. 2014; 24(7):356-366.
• [14]Khan E, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, Alper B, Paramesh A, Buell J, Zhang R. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol. 2014; 3(3):107-113.
• [15]Lecefel C, Eloy P, Chauvin B, Wyplosz B, Amilien V, Massias L, Taburet AM, Francois H, Furlan V. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. J Clin Pharm Ther. 2014.
• [16]Chiu KW, Hu TH, Nakano T, Chen KD, Lai CY, Hsu LW, Tseng HP, Chiu HC, Cheng YF, Goto S, Chen CL. Biological interaction of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation. Transplant Res. 2013; 2(1):6.
• [17]Ma B, Wang J, Sun J, Li M, Xu H, Sun G, Sun X. Permeability of rhynchophylline across human intestinal cell in vitro. Int J Clin Exp Pathol. 2014; 7(5):1957-66.
• [18]Chen YK, Han LZ, Xue F, Shen CH, Lu J, Yang TH, Zhang JJ, Xia Q. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS One. 2014; 9(10):e109464.
• [19]Tsukimoto M, Ohashi R, Torimoto N, Togo Y, Suzuki T, Maeda T, Kagawa Y. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2014.
• [20]Mustafa A, Cenayko C, Mitry RR, Quaglia A. Laser microdissection microscopy: application to cell culture. Methods Mol Biol. 2012; 806:385-392.
• [21]Aini W, Miyagawa-Hayashino A, Ozeki M, Tsuruyama T, Tamaki K, Uemoto S, Haga H. Frequent hepatocyte chimerism in long-term human liver allografts independent of graft outcome. Transpl Immunol. 2013; 28(2–3):100-105.
• [22]Kandathil AJ, Graw F, Quinn J, Hwang HS, Torbenson M, Perelson AS, Ray SC, Thomas DL, Ribeiro RM, Balagopal A. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology. 2013; 145(6):1404-1413.e1-10.
• [23]Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull. 2013; 36(11):1814-1821.
• [24]Gómez-Bravo MA, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, Pons JA, Alamo JM, Millán O, Brunet M. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol. 2013; 53(11):1146-1154.
• [25]Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther. 2010; 88(1):95-100.